DEF: TAO Synergies Seeks Shareholder Approval for Key Financing, Equity Plan Expansion

Sentiment:

Proxy Statement


TAO Synergies Inc. calls for its 2025 annual meeting to vote on a director election, authorization of common stock issuance for a recent financing, an increase in its equity incentive plan, and auditor ratification.

Delay expectedThe Adjournment Proposal seeks stockholder approval to adjourn the annual meeting to a later date or dates if there are insufficient votes to adopt either the Issuance Proposal or the Plan Amendment Proposal, or to establish a quorum.
Capital raiseOn October 13, 2025, the company entered into a Securities Purchase Agreement for a private placement (the 'Financing').The Financing involved the sale of 11,000 shares of newly designated Series E Preferred Stock, initially convertible into up to 1,375,000 shares of common stock at an initial conversion price of $8.00 per share.Warrants were also issued to purchase up to an aggregate of 1,375,000 shares of common stock at an initial exercise price of $8.00 per share.The Financing yielded gross proceeds of $11.0 million.In connection with the Financing, GP Nurmenkari Inc., as placement agent, received warrants to purchase 55,000 shares of common stock at an exercise price of $8.00 per share.The company is seeking stockholder approval for the issuance of common stock underlying these securities to comply with Nasdaq Listing Rule 5635(d), as the potential issuance exceeds 20% of outstanding common stock.The company agreed to offer investors in this financing the opportunity to participate in any subsequent securities offerings.

Summary

  • The 2025 annual meeting of stockholders will be held virtually on Thursday, December 18, 2025, at 11:00 am Eastern Time.
  • Stockholders will vote on the election of one director (Bruce T. Bernstein) for a three-year term expiring in 2028.
  • Approval is sought for the issuance of common stock underlying convertible preferred stock and warrants from a private placement financing, to comply with Nasdaq Listing Rule 5635(d).
  • The financing, dated October 13, 2025, raised gross proceeds of $11.0 million through the sale of 11,000 shares of Series E Preferred Stock (convertible into up to 1,375,000 common shares at an initial $8.00 conversion price) and warrants to purchase up to 1,375,000 common shares at an initial $8.00 exercise price.
  • GP Nurmenkari Inc., as placement agent, received warrants to purchase 55,000 shares of common stock at an $8.00 exercise price.
  • A proposed amendment to the TAO Synergies Inc. 2020 Equity Incentive Plan seeks to increase the number of shares available for awards by 500,000, bringing the total to 3,175,000 shares.
  • Stockholders will also vote to ratify the appointment of Stephano Slack LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
  • An Adjournment Proposal seeks approval to adjourn the meeting if necessary to solicit additional proxies for the Issuance Proposal or Plan Amendment Proposal, or to establish a quorum.
  • As of June 30, 2025, cash and cash equivalents were approximately $14.37 million.
  • The company's name changed from Synaptogenix, Inc. to TAO Synergies Inc. on June 26, 2025, with the ticker symbol changing from SNPX to TAOX.

Sentiment

Score: 5

Explanation: The filing presents standard corporate governance proposals for an annual meeting, including a necessary capital raise and an equity plan expansion, which are crucial for the company's operational continuity and talent retention. While the $11.0 million financing provides essential working capital and supports the company's unique 'differentiated cryptocurrency treasury strategy,' it also introduces significant potential dilution for existing shareholders. The anti-dilution provisions in the new securities could exacerbate this. The overall sentiment is neutral to slightly cautious due to the dilution and the speculative nature of the crypto strategy, balanced by the capital infusion.

Positives

  • A private placement financing on October 13, 2025, successfully raised $11.0 million in gross proceeds, providing capital for general corporate purposes and working capital.
  • The financing supports the company's 'differentiated cryptocurrency treasury strategy,' including the continued acquisition of Bittensor TAO as a treasury reserve asset.
  • The proposed increase in the 2020 Equity Incentive Plan aims to attract, retain, and motivate key employees, consultants, and directors, aligning their interests with the company's long-term success.
  • The Board of Directors recommends a vote in favor of all proposals, indicating unified management support for these strategic actions.

Negatives

  • The financing transaction involves significant potential dilution to existing common stockholders, as the issuance of common stock underlying Series E Preferred Stock and Warrants (including GPN Warrants) could exceed 20% of outstanding shares.
  • The anti-dilution provisions contained in the Series E Preferred Stock and Warrants could further reduce conversion or exercise prices, leading to greater future dilution.
  • Failure to approve the Issuance Proposal could require the company to pay substantial cash amounts to the holders of the Securities, for which it does not anticipate having sufficient funds, potentially jeopardizing its business plan.
  • The proposed increase of 500,000 shares for the 2020 Equity Incentive Plan also contributes to potential future dilution for current stockholders.
  • Executive compensation for Robert Weinstein was $565,876 in 2024, which may be considered high relative to the company's stated cash position and stage.

Risks

  • **Dilution Risk**: Significant dilution to current stockholders from the potential issuance of common stock underlying Series E Preferred Stock and Warrants, especially due to anti-dilution provisions that may reduce conversion/exercise prices.
  • **Financial Risk**: If the Issuance Proposal is not approved, the company may be required to make substantial cash payments to security holders, for which it does not anticipate having sufficient funds, potentially jeopardizing its ability to execute its business plan.
  • **Market Price Decline**: The issuance or resale of common stock from the financing could cause the market price of the company's common stock to decline.
  • **Anti-Takeover Effect**: The increase in the number of issued shares of common stock in connection with the financing may have an incidental anti-takeover effect by potentially diluting the stock ownership of parties seeking control.
  • **Operational Risk**: Loss of potential funds from warrant exercises (if the Issuance Proposal is not approved) could jeopardize the company's ability to execute its business plan.
  • **Cryptocurrency Strategy Risk**: The 'differentiated cryptocurrency treasury strategy' and acquisition of Bittensor TAO introduces exposure to the inherent volatility and risks associated with digital asset markets.

Future Outlook

The company intends to use the $11.0 million gross proceeds from the recent financing for general corporate purposes and working capital, including the continued acquisition of Bittensor TAO as a treasury reserve asset. The proposed increase in the 2020 Equity Incentive Plan is deemed essential to attract, retain, and motivate present and future key employees, consultants, and directors, thereby supporting the company's sustained progress, growth, and profitability.

Management Comments

  • "We have decided to hold this year's annual meeting virtually via live audio webcast on the internet." (Joshua Silverman, Executive Chairman)
  • "The board of directors recommends a vote in favor of the director nominated for election and the approval of each of these proposals." (Joshua Silverman, Executive Chairman)
  • "We hope you will be able to attend the annual meeting. Whether you plan to attend the annual meeting or not, it is important that you cast your vote either in person or by proxy." (Joshua Silverman, Executive Chairman)
  • "We believe that the Financing, which yielded gross proceeds of $11.0 million, was necessary in light of the Company's cash and funding requirements at the time and the progression of the Company's differentiated cryptocurrency treasury strategy." (Company statement regarding financing)
  • "We also believe that the anti-dilution protections contained in the Series E Preferred Stock and Warrants were reasonable in light of market conditions and the size and type of the Financing, and that we would not have been able to complete the sale of the Series E Preferred Stock and Warrants unless such anti-dilution provisions were offered." (Company statement regarding financing terms)
  • "Our Board, the Compensation Committee and management believe that the effective use of stock-based long-term incentive compensation is vital to our ability to achieve strong performance in the future." (Company statement regarding Plan Amendment)
  • "Our Board believes that the number of shares currently remaining available for issuance pursuant to future awards under the Plan (as of October 31, 2025) is not sufficient for future granting needs." (Company statement regarding Plan Amendment)

Industry Context

The company's adoption of a 'differentiated cryptocurrency treasury strategy' involving the acquisition of 'Bittensor TAO' positions it uniquely within the market, diverging from traditional corporate treasury practices. This strategy introduces exposure to the highly volatile and rapidly evolving digital asset industry, which carries both significant potential upside and increased risk compared to companies with conventional treasury management. The need for stockholder approval for substantial equity issuance is a standard requirement for Nasdaq-listed companies, reflecting regulatory efforts to protect shareholders from excessive dilution in non-public offerings.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Executive Chairman of the BoardNAJoshua N. SilvermanAugust 2025Appointment to new executive role.
DirectorNARobert EphronAugust 29, 2025Appointment to the Board of Directors.
Chief Executive OfficerAlan J. Tuchman, M.D.NAJune 8, 2025Resignation from CEO role; continued as Chief Medical Officer and board member until August 28, 2025.
Board MemberAlan J. Tuchman, M.D.NAAugust 28, 2025Resignation from the Board and all committees.
Chief Scientific Officer and PresidentDaniel L. Alkon, M.D.NAJune 4, 2025Resignation from officer and director roles to become a consultant (consulting agreement terminated October 3, 2025).
Board MemberJonathan L. SchechterNAAugust 2025Resignation from the Board of Directors.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Board CompositionThe Board is divided into three classes, with one class elected annually for a three-year term. Bruce T. Bernstein's term expires at the 2025 annual meeting, Robert Ephron's in 2026, and Joshua N. Silverman and William S. Singer's in 2027.NAEnsures staggered board elections, promoting continuity and potentially stability in governance.
Committee CompositionThe Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee have updated compositions, reflecting recent director changes (e.g., Robert Ephron's appointment and Jonathan L. Schechter's resignation). All members of these committees are determined to be independent under Nasdaq rules.Post-December 31, 2024Maintains independent oversight functions for key areas like financial reporting, executive compensation, and director nominations, in compliance with Nasdaq standards.
Insider Trading PolicyThe company has an insider trading policy prohibiting personnel (directors, officers, employees, consultants) from trading company securities while in possession of material non-public information, engaging in short-term speculative swings (holding less than six months), short sales, hedging devices, or non-recourse pledges. It also requires pre-clearance for certain transactions.NA (policy in effect)Designed to prevent violations of insider trading laws, avoid the appearance of improper conduct, and promote ethical trading practices among personnel.
Related Person Transactions PolicyThe Audit Committee Charter requires advance approval for all future transactions between the company and any related person (director, executive officer, 5%+ holder, immediate family, or affiliates) involving $120,000 or more. Such transactions must be on terms no less favorable to the company than those obtainable from unaffiliated third parties.NA (policy in effect)Ensures transparency, fairness, and mitigates potential conflicts of interest in dealings with related parties, protecting the company's and stockholders' interests.
Board Leadership StructureThe Board has elected to combine the positions of Chair and Chief Executive Officer, with Joshua N. Silverman serving as Executive Chairman.NA (current structure)Provides unified leadership and clear direction, but may reduce the perceived independence of board oversight compared to a split role.

Related Party Transactions

  • Since January 1, 2024, the company has not engaged in any related party transactions that would require disclosure under Item 404 of Regulation S-K.

Stakeholder Impact

  • **Shareholders**: Face potential significant dilution from the issuance of common stock related to the financing and the increase in the equity incentive plan. There is a risk of market price decline due to increased share count. However, the financing provides necessary capital for the company's operations and strategic initiatives.
  • **Employees/Management**: The proposed increase in the equity incentive plan is intended to attract, retain, and motivate key personnel, potentially benefiting employees through stock awards and aligning their interests with company performance.
  • **Investors (Series E Preferred Stock & Warrants)**: These investors receive preferred stock and warrants with anti-dilution provisions, offering protection and potential upside. They also have the right to participate in future securities offerings, providing preferential access to future capital raises.
  • **Placement Agent (GP Nurmenkari Inc.)**: Received warrants for 55,000 shares of common stock and an 8.0% cash fee from the gross proceeds of the financing, directly benefiting from the transaction.

Next Steps

  • Stockholders are urged to vote on the proposals by December 17, 2025 (for Internet/telephone) or at the Annual Meeting on December 18, 2025.
  • The company will publish preliminary or final voting results in a Current Report on Form 8-K within four business days of the annual meeting.
  • If the Issuance Proposal is approved, the company will be able to issue common stock upon conversion/exercise of the Series E Preferred Stock and Warrants.
  • If the Plan Amendment Proposal is approved, the 2020 Equity Incentive Plan will have an additional 500,000 shares available for awards.
  • The Audit Committee will reconsider the appointment of Stephano Slack LLC if stockholders do not ratify it.
  • The company plans to continue its 'differentiated cryptocurrency treasury strategy,' including the acquisition of Bittensor TAO.

Key Dates

DateDescription
August 23, 2013Synaptogenix (formerly Neurotrope Bioscience, Inc.) became a wholly owned subsidiary of Neurotrope, Inc.
October 1, 2013Effective date of Robert Weinstein's employment agreement with Neurotrope, Inc., later assumed by Synaptogenix.
September 1, 2022Morison Cogen LLP engaged as independent registered public accounting firm.
March 29, 2023Company adopted a new non-employee director compensation policy.
June 16, 2023Second amendment to Dr. Tuchman's employment agreement, extending term through June 7, 2024.
December 20, 2023Stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing shares by 3,000,000 (adjusted to 175,000 after reverse stock split).
March 2024Mr. Weinstein paid a $150,000 bonus for 2023 services; Drs. Tuchman and Alkon each paid a $75,000 bonus for 2023 services.
April 4, 20241-for-25 reverse stock split of common stock effectuated.
June 20, 2024Third amendment to Dr. Tuchman's employment agreement, extending term through December 7, 2024.
September 30, 2024Morison Cogen LLP resigned as independent registered public accounting firm.
October 4, 2024Stephano Slack LLC engaged as the new independent registered public accounting firm.
November 2024Dr. Tuchman's base salary amended to $12,500 per month, effective January 1, 2025.
December 6, 2024Stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing shares by 500,000 to 675,000 shares.
January 1, 2025Dr. Alkon's compensation reduced to $16,000 per month.
June 4, 2025Dr. Alkon resigned as Chief Scientific Officer and President, becoming a consultant (consulting agreement later terminated).
June 8, 2025Dr. Tuchman resigned as Chief Executive Officer, continuing as Chief Medical Officer and a board member.
June 25, 2025Company filed Certificate of Amendment to change name to TAO Synergies Inc.
June 26, 2025Name change from Synaptogenix, Inc. to TAO Synergies Inc. became effective; ticker symbol changed from SNPX to TAOX.
July 1, 2025Effective date of Joshua N. Silverman's Executive Compensation Agreement.
August 6, 2025Stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing shares by 2,000,000 to 2,675,000 shares.
August 14, 2025Company entered into an Executive Compensation Agreement with Joshua N. Silverman.
August 28, 2025Dr. Tuchman resigned from his position as a member of the Board and all committees.
August 29, 2025Robert Ephron appointed to the Board of Directors.
October 3, 2025Company delivered notice of termination to Dr. Alkon for his consulting agreement.
October 13, 2025Securities Purchase Agreement entered into for private placement financing.
October 28, 2025Board nominated Bruce T. Bernstein for election; Board approved amendment to the 2020 Equity Incentive Plan.
October 29, 2025Record date for stockholders entitled to vote at the annual meeting.
October 31, 2025Date for beneficial ownership and equity compensation plan information.
November 14, 2025Closing market price per share of common stock was $6.60.
November 17, 2025Date of the Proxy Statement.
On or about November 18, 2025Intended start of distribution of proxy materials to stockholders.
December 17, 2025Deadline for Internet or telephone proxy voting (11:59 p.m. Eastern Time).
December 18, 2025Annual Meeting of Stockholders to be held at 11:00 a.m. Eastern Time.
December 31, 2025Fiscal year ending for auditor ratification; deadline for company to seek stockholder approval for securities issuance.
2028Term expiration for elected director Bruce T. Bernstein.
November 3, 2030Expiration of the 2020 Equity Incentive Plan.

Recommendation

hold

The proxy statement outlines necessary corporate actions, including a capital raise and an expansion of the equity incentive plan, which are crucial for the company's operational continuity and talent retention. While the $11.0 million financing provides essential working capital and supports the company's unique 'differentiated cryptocurrency treasury strategy,' it also introduces significant potential dilution for existing shareholders. The anti-dilution provisions in the new securities could exacerbate this. The company's reliance on shareholder approval for the issuance of these shares, with a stated risk of insufficient funds if not approved, highlights a critical juncture. Given the mixed signals of necessary capital infusion versus substantial dilution and the speculative nature of the crypto treasury strategy, a 'hold' recommendation is appropriate as investors should monitor the outcome of the shareholder votes and the execution of the business plan, particularly the crypto strategy, before making further investment decisions.

Keywords

TAO Synergies, Proxy Statement, Annual Meeting, Stockholder Approval, Equity Financing, Convertible Preferred Stock, Warrants, Stock Dilution, Equity Incentive Plan, Corporate Governance, Auditor Ratification, Nasdaq Listing Rule 5635(d), Bittensor TAO, Cryptocurrency Treasury

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.